Investors say executive pay packages at pharma may incentivize drug pricing risks
In resolutions at five U.S. drug makers, investors request a review of compensation policies that may drive senior execs to ignore the long-term business risks of skyrocketing drug costs. Falls Church, Va., 12/14/17 – Investors today announced they have filed resolutions at five major pharmaceutical companies asking for information about how well executive pay incentives mitigate […]
